Arcus Biosciences, Inc.
RCUS
$9.34
-$0.20-2.10%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -45.83% | 23.08% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -45.83% | 23.08% | |||
| Cost of Revenue | -17.89% | 1,130.00% | |||
| Gross Profit | 0.00% | -358.62% | |||
| SG&A Expenses | -6.67% | 0.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.69% | 5.52% | |||
| Operating Income | 1.90% | 0.94% | |||
| Income Before Tax | -1.09% | 1.08% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2.17% | 1.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.17% | 1.08% | |||
| EBIT | 1.90% | 0.94% | |||
| EBITDA | 2.91% | 0.96% | |||
| EPS Basic | -1.84% | 1.40% | |||
| Normalized Basic EPS | -0.76% | 1.39% | |||
| EPS Diluted | -1.84% | 1.40% | |||
| Normalized Diluted EPS | -0.76% | 1.39% | |||
| Average Basic Shares Outstanding | 0.33% | 0.33% | |||
| Average Diluted Shares Outstanding | 0.33% | 0.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
